Kalaris Therapeutics

KLRSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$77.128 M

$3.24 -0.15%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$43.4M

Loss-making

Shares outstanding

23,804,981

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#116Pelthos TherapeuticsPTHS$89.0M
#117Greenland MinesGRML$82.8M
#118Kalaris TherapeuticsKLRS$77.1M
#119Champions OncologyCSBR$73.6M
#120BioStem TechnologiesBSEM$71.0M

What if Kalaris Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$1,270,069

Per share 391,997× higher

Bitcoin $1.74T

$73,163.47

Per share 22,581× higher

Nvidia $5.52T

$231,706.42

Per share 71,514× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Kalaris Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.